Blog

Over the past two decades, Australia has experienced a steady rise in hospital admissions for respiratory diseases.ⁱ These conditions often bring distressing symptoms, from shortness of breath to overwhelming anxiety, placing significant physical and emotional strain on patients. For healthcare professionals, it’s important to have access to treatment solutions that can alleviate these signs and improve patient comfort while the underlying condition is treated.

Nitric oxide is used in specialised medical settings to help manage certain serious respiratory conditions under the care of healthcare professionals. As a potent vasodilator, it is often delivered as an inhaled therapy, providing rapid onset relief with a predictable duration of effects. However, its administration requires careful monitoring and specialised equipment to ensure appropriate dosing and patient safety.ⁱⁱ

Traditionally, inhaled nitric oxide (iNO) therapy has been delivered to patients using cylinder-based systems. These systems are widely used around the world and contain nitric oxide mixed with inert gases such as nitrogen to ensure stability during storage and transport.^v

Cylinder-based systems are associated with several operational requirements. They often demand specific protocols and comprehensive staff training to ensure safe and effective use. Additionally, costs associated with acquiring, maintaining, and handling cylinder-based systems can be significant.ⁱⁱⁱ Further considerations include the technical complexity of the equipment and adherence to safety measures required for the production, storage, and administration of medical gases. These factors can impact both the physical space required within healthcare facilities and the time and resources allocated by healthcare staff.^iv

To address the operational demands of traditional systems, newer technologies have emerged to simplify nitric oxide delivery. Cylinder-free iNO delivery systems now provide a practical alternative, offering several benefits for healthcare professionals and patients alike.

One of the key advantages of these systems is the elimination of gas cylinders. Instead, iNO is generated directly from room air, creating an unlimited supply and removing the need for constant monitoring of cylinder levels or replacements. The simplified setup also reduces the training required for respiratory therapy staff and minimises storage and handling requirements within the clinical environment.

Among these innovations is the LungFit® PH from Beyond Air, now available through Getz Healthcare in Australia and New Zealand. Using patented Plasma Pulse Technology™, LungFit® PH generates iNO on demand from room air, ensuring a consistent and unrestricted supply. The system enables therapy initiation within one minute, easing staff workload and allowing greater focus on patient care. Its filter predictably operates for 12 hours regardless of dose or gas flow, delivering iNO concentrations between 0.1–80 ppm at flow rates of 0.5–100 L/min. With four hours of battery backup and no need for gas storage, hazardous materials, or bulky equipment, LungFit® PH offers both safety and convenience for modern respiratory care.^v,vi

To unburden your respiratory therapy team, Discover the Future of Respiratory Support with LungFit® PH!

Get in touch with the Getz Healthcare team to learn more. 

ⁱ Alrajeh A, Naser AY, Aldabayan YS, et al Hospitalisation patterns for respiratory diseases in Australia: an ecological study. BMJ Open 2024;14:e084286. doi: 10.1136/bmjopen-2024-084286

ⁱⁱ Witek J, Lakhkar AD. Nitric Oxide. [Updated 2023 Aug 28]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554485/

ⁱⁱⁱ Gianni S, Carroll RW, Kacmarek RM, Berra L. Inhaled Nitric Oxide Delivery Systems for Mechanically Ventilated and Nonintubated Patients: A Review. Respir Care. 2021 Jun;66(6):1021-1028. doi: 10.4187/respcare.08856. PMID: 34039761; PMCID: PMC10408459.

^iv Kaplish D, Vagha JD, Meshram RJ, Lohiya S. A Comprehensive Review of Inhaled Nitric Oxide Therapy: Current Trends, Challenges, and Future Directions. Cureus. 2024 Feb 4;16(2):e53558. doi: 10.7759/cureus.53558. PMID: 38445143; PMCID: PMC10913844.

^v LungFit PH System Operator’s Manual. Garden City, NY: Beyond Air Inc. 2022.

^vi Data on file. Beyond Air Inc. 2025.